Viyash Scientific Ltd Q1 FY26 Earnings Analysis

Published 4 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹8.9K Cr

Price

264

Market Cap

₹8.9K Cr

P/E Ratio

69.7

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Viyash Scientific Ltd Q1 FY26 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Viyash Scientific Ltd share price analysis?

Viyash Scientific Ltd currently shows a neutral. The stock trades at a P/E of 69.7 with a market cap of ₹8,901. Investors should review the full earnings analysis for detailed insights.

Is Viyash Scientific Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Pharmaceuticals & Biotechnology this season

  • Torrent Pharmaceuticals Ltd (Q1 FY26)

    Torrent Pharmaceuticals Ltd Q1 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹149,109

  • SMS Pharmaceuticals Ltd (Q1 FY26)

    SMS Pharmaceuticals Ltd Q1 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹3,750, P/E

  • J B Chemicals & Pharmaceuticals Ltd (Q1 FY26)

    J B Chemicals & Pharmaceuticals Ltd Q1 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap

  • Granules India Ltd (Q1 FY26)

    Granules India Ltd Q1 FY26 quarterly results analysis. - Oncology portfolio expected to start yielding revenues from FY '28 onwards, with a broad pipeline inclu